Eli Lilly (NYSE: LLY) stock has soared 400% over the past five years, and though the momentum slowed in the early months of this year, it's now on the rise again. The stock has advanced 25% over the past six months, buoyed by optimism about Lilly's weight loss drug portfolio. Lilly is the maker of tirzepatide, sold under the names Mounjaro for type 2 diabetes and Zepbound for weight loss, and these blockbuster products have been driving explosive revenue growth.
POLARIS INSIGHTS